Cytheris Receives €1.5M Loan for HCV Clinical Development
BioWorld International Correspondent
PARIS - Cytheris SA has received a €1.5 million (US$2.3 million) interest-free loan from OSEO, France's national industrial innovation agency, to support its continuing clinical development program in hepatitis C (HCV).
The funds will enable Paris-based Cytheris to push ahead with the development of its lead product, recombinant human Interleukin-7 (r-hIL-7), a critical growth factor for immune T-cell recovery and enhancement.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST